U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408505) titled 'Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer' on Jan. 23.
Brief Summary: Cancer anorexia-cachexia syndrome is a common and severe complication in patients with advanced cancer, with a particularly high prevalence in pancreatic cancer. It is associated with systemic inflammation, metabolic disturbances, and dysregulation of central appetite control, leading to reduced quality of life, poor tolerance to anticancer therapy, and shortened survival. Anticancer treatments, including chemotherapy and immunotherapy, may further exacerbate the development and progression of cachexia.
Megestrol acetate is recommen...